While GLP-1 receptor agonists have been linked to temporary worsening of diabetic retinopathy, this appears driven by rapid blood sugar reduction rather than the drugs themselves, and claims linking semaglutide to optic nerve damage remain inconclusive.
Rapid HbA1c drop, not drug effectRetinopathy worsening after GLP-1 agonist use appears to be caused by swift blood sugar improvement — a known phenomenon with any effective diabetes treatment, not unique to GLP-1 drugs
What the researchers found
The review reached several key conclusions about GLP-1 receptor agonists and eye health:
1. Preclinical studies hint at possible retinal protective effects of GLP-1 agonists
2. Clinical cases of retinopathy worsening after GLP-1RA use are likely due to rapid reduction in glycated hemoglobin (HbA1c) levels rather than the drug's mechanism of action — a phenomenon known as 'early worsening' that occurs with any treatment that rapidly improves blood sugar control
3. Evidence linking semaglutide specifically to nonarteritic anterior ischemic optic neuropathy (NAION) remains inconclusive and limited by methodological constraints
4. Large-scale, well-designed studies are needed to clarify both potential associations and guide clinical practice
Why it matters
With tens of millions of people now taking GLP-1 drugs, even a small increase in eye complication risk could affect enormous numbers of patients. Many people taking these drugs for diabetes already have retinopathy or are at risk for it. Clinicians need clear guidance on whether to screen more aggressively, adjust dosing speed, or warn patients about eye risks. This review helps separate genuine safety signals from the expected consequences of rapid blood sugar improvement.
How the study worked
This is a narrative review synthesizing relevant publications including meta-analyses, randomized controlled trials, post hoc analyses, and preclinical in vitro and in vivo research. The literature search used WorldCat Discovery, PubMed, and Google Scholar databases. The review evaluated both the diabetic retinopathy and NAION associations separately.
What this study cannot tell us
As a narrative review, this does not use systematic methodology or quantitative meta-analysis. The evidence base for both associations is relatively limited — most retinopathy data comes from post hoc analyses of trials not designed to study eye outcomes, and NAION evidence is largely from case reports and observational studies with significant confounders. The review cannot definitively rule out a causal relationship for either condition. Publication bias may affect the available literature in both directions.
How to read the evidence
This is a narrative review synthesizing meta-analyses, RCTs, post hoc analyses, and preclinical research. The quality of the underlying evidence varies considerably — from well-designed RCTs to case reports. The review provides a useful overview but cannot offer definitive conclusions due to the limitations of the available data.
When this study was published
Published in 2025, this review is highly current and addresses a safety debate that intensified in 2023-2024 as GLP-1 agonist prescribing exploded. The conclusions reflect the latest available evidence.
The bigger picture
This controversy highlights a broader challenge with the GLP-1 agonist revolution: as these drugs are prescribed to increasingly large populations for both diabetes and obesity, rare or subtle adverse effects may emerge that were not apparent in clinical trials. The distinction between drug-caused harm and expected physiological consequences of effective treatment (like early worsening of retinopathy with any rapid glucose improvement) is critical for making sound prescribing decisions. Similar safety surveillance questions are arising for GLP-1 drugs across multiple organ systems.
Questions still open
- Should patients with existing diabetic retinopathy receive slower dose titration of GLP-1 agonists to minimize the risk of early worsening?
- Do GLP-1 agonists' potential retinal protective effects translate into long-term reduction in retinopathy progression once blood sugar stabilizes?
- Would prospective ophthalmologic monitoring studies during GLP-1 agonist treatment provide clearer safety data than the current retrospective evidence?
Common questions
Should people with diabetic eye disease avoid taking GLP-1 drugs?
What is NAION and should semaglutide users be worried about it?
Read the original research
In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy.
Canadian journal of diabetes, 49(7), 401-410
Citation
Nadeem, Nadia; Al Issa, Raghad Mazin; Shah, Asnin; Wardeh, Rahaf; Rashid, Fauzia; Abdelgadir, Elamin Ibrahim; Bashier, Alaaeldin. (2025). In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy.. Canadian journal of diabetes, 49(7), 401-410. https://doi.org/10.1016/j.jcjd.2025.07.002